Hostname: page-component-74656f9884-skzmx Total loading time: 0 Render date: 2026-11-06T11:32:36.256Z Has data issue: false hasContentIssue false
  • English
  • Français

Crystal structure and X-ray powder diffraction data for Lumateperone tosylate

Published online by Cambridge University Press:  27 October 2023

Jiyong Liu ,
Dier Shi ,
Shuna Liu  and
Xiurong Hu Open the ORCID record for Xiurong Hu [Opens in a new window]
Jiyong Liu
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310058, PR China
Dier Shi
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310058, PR China
Shuna Liu
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310058, PR China
Xiurong Hu*
Affiliation:
Department of Chemistry, Zhejiang University, Hangzhou 310058, PR China
*
a)Author to whom correspondence should be addressed. Electronic mail: huxiurong@zju.edu.cn

Abstract

X-ray powder diffraction data, unit-cell parameters, and space group for the Lumateperone tosylate, C24H29FN3O⋅C7H7O3S, are reported [a = 15.5848(10) Å, b = 6.0700(4) Å, c = 31.3201(14) Å, β = 96.544(5)°, V = 2943.58 Å3, Z = 4, and space group C2]. In each case, all measured lines were indexed and were consistent with the corresponding space group. The single-crystal data of Lumateperone tosylate is also reported, respectively [a = 15.626(3) Å, b = 6.0806(10) Å, c = 31.415(5) Å, β = 96.609(7)°, V = 2965.1(8) Å3, Z = 4, and space group C2]. The experimental powder diffraction pattern has been well matched with the simulated pattern derived from the single-crystal data with preferred orientation in the [002] direction (orientation coefficient = 0.75).

Keywords

X-ray powder diffraction dataLumateperone tosylatesolid-state formpreferred orientation

Information

Type
New Diffraction Data
Information
Powder Diffraction , Volume 40 , Issue 1 , March 2025 , pp. 94 - 98
Check for updates
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of International Centre for Diffraction Data

I. INTRODUCTION

Lumateperone (Lumateperone tosylate, ITI-007, 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3′′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluoro-phenyl)-butan-1-one 4-methylbenzenesulfonate) is a novel, orally available agent for the treatment of schizophrenia and other neuropsychiatric and neurological disorders (Blair, Reference Blair2020; Mazza et al., Reference Mazza, Marano, Traversi, Sani and Janiri2020; Maini et al., Reference Maini, Hollier, Gould, Bollich, John LaForge, Cornett, Edinoff, Kaye and Kaye2021; Pahwa et al., Reference Pahwa, Sleem, Elsayed, Good and El-Mallakh2021). Due to its ability to modulate serotonin, dopamine, and glutamate neurotransmission, Lumateperone can be considered a multi-target-directed ligand and a multifunctional modulator of the serotoninergic system with possible precognitive, antipsychotic, antidepressant, and anxiolytic properties, implicated in serious mental illness (Kumar et al., Reference Kumar, Kuhad and Kuhad2018; Frampton, Reference Frampton2020; Greenwood et al., Reference Greenwood, Acharya, Marcellus and Rey2021; Maini et al., Reference Maini, Hollier, Gould, Bollich, John LaForge, Cornett, Edinoff, Kaye and Kaye2021; Syed and Brasic, Reference Syed and Brasic2021; Cao et al., Reference Cao, Yu, Wang, Luo, Liu, He, Qi, Fan, Tang, Chen, Li, Cheng and Wang2022; Titulaer et al., Reference Titulaer, Radhe, Danielsson, Dutheil, Marcus, Jardemark, Svensson, Snyder, Ericson, Davis and Konradsson-Geuken2022). Thus, in December 2019, the U.S. Food and Drug Administration (FDA) approved Lumateperone for the treatment of patients with schizophrenia. The chemical structure of Lumateperone is shown in Figure 1 and its salts, such as Lumateperone tosylate (Wennogle and Tomesch, Reference Wennogle and Tomesch2008), ditosylate (Janton et al., Reference Janton, Cerić, Matečić, Mrsic, Lerman, Momcilovic, Sagud and Jegorov2016), oxalate, 4-aminosalicylate, cyclamate (Wennogle et al., Reference Wennogle, Li and Aret2016), chlorhydrate (Li and Wennogle, Reference Li and Wennogle2017), besylate (Janton et al., Reference Janton, Cerić, Matečić, Mrsic, Lerman, Momcilovic, Sagud and Jegorov2018), mono/di-naphthalenesulfonate (Lengauer et al., Reference Lengauer, Pichler and Margreiter2019), and isonicotinamide and nicotinamide (Wennogle et al., Reference Wennogle, Li and Aret2016) were reported, but their crystal structures have not been reported yet. The current clinically available Lumateperone product ITI-007 is Lumateperone tosylate.

Figure 1.

Chemical structure of Lumateperone.

We have not found this compound in the CSD database (Groom et al., Reference Groom, Bruno, Lightfoot and Ward2016) or in the PDF4+ database (Gates-Rector and Blanton, Reference Gates-Rector and Blanton2019). Therefore, we have decided to characterize this compound by X-ray powder diffraction (XRD) technique and X-ray single-crystal diffraction techniques. In our study, we present powder data for Lumateperone tosylate.

II. EXPERIMENTAL

A. Sample preparations

The sample was supplied by Zhejiang Ausun Pharmaceutical Co., LTD (purity >99.9%) and used without further purification. Dissolving Lumateperone tosylate (1.0 g) in the methanol (5 mL) at 50−60°C and slow cooling of the solutions yielded needle crystals of Lumateperone tosylate. Then, the crystals were dried, smashed, and front-loaded into a zero background plate and limited force was used to make the sample surface flat.

B. Powder diffraction data collection

XRD data were collected at room temperature on Bruker D8 Discover diffractometer with parafocusing Bragg–Brentano geometry and one-dimensional LynxEye XE-T detector using a Cu Kα radiation (λ = 1.5418 Å), and operated at 42 kV and 100 mA. The scan 2θ range was from 2° to 50° with a step size of 0.02° and a counting time of 2.0 s/step. In order to reduce the influence of preference orientation, rotating modes with a speed rate of 20 r/min were used. The software package MDI-Jade version 9.4 (Materials Data Inc., USA) (MDI, 2009) was used to smooth the data, fit the background, and eliminate the Kα2 component and the top of the smoothed peaks were used to determine the peak positions and intensities of the diffraction peaks (Table I). The d-spacing was calculated using Cu Kα 1 radiation (λ = 1.5406 Å).

TABLE I.

X-ray powder diffraction data of Lumateperone tosylate

C. Single-crystal diffraction data collection

X-ray single-crystal diffraction data were collected at room temperature with a Bruker D8 Venture diffractometer with Ga Kα radiation (λ = 1.34139 Å) for cell determination and subsequent data collection. Data reduction was performed by APEX4 software and multi-scan absorption correction was applied. Using Olex2 (Dolomanov et al., Reference Dolomanov, Bourhis, Gildea, Howard and Puschmann2009), the crystal structure was solved by ShelXT (Sheldrick, Reference Sheldrick2015a) and refined with full-matrix least-squares methods with anisotropic thermal parameters for all non-hydrogen atoms on F2 using SHELXL (Sheldrick, Reference Sheldrick2015b). Diamond (Brandenburg and Putz, Reference Brandenburg and Putz2005) was used to prepare the figures and packing diagrams.

III. RESULTS AND DISCUSSION

Indexing of the experimental XRD patterns and unit-cell refinements was done using MDI-Jade. In the process of refinement, only zero-offset parameter (−0.00102°) was added and refined. The cell refinement results showed that Lumateperone tosylate is monoclinic with space group C2 and unit-cell parameters: a = 15.5848(10) Å, b = 6.0700(4) Å, c = 31.3201(14) Å, β = 96.544(5)°, unit-cell volume V = 2943.58 Å3, Z = 4. The figure of merit is F 30 = 422.3(30) (Smith and Snyder, Reference Smith and Snyder1979). The values of 2θ obs, d obs, I obs, h, k, l, 2θ cal, d cal, and Δ2θ are listed in Table I.

Based on the single-crystal data, the structures of Lumateperone tosylate were solved and refined. The detailed crystallographic information is summarized in Table II and the asymmetric units with the corresponding atom labeling scheme are illustrated in Figure 2(a). In the crystal structure, the expected proton transfer was found between Lumateperone and toluene sulfonic acid, forming Lumateperone cation protonated at the N atom of the hydro-pyridine group. Hydrogen bonds N1–H1⋯O3 linked Lumateperone cations and tosylate anions. In Figure 2(b), two chiral C atoms (C12, C22) of Lumateperone molecules existed “R” and “S” configurations, respectively. The hydrogen bonds (N1–H1⋯O3 and C29–H29C⋯O4) between Lumateperone cations and tosylate anions linked Lumateperone molecules into an infinite straight chain along the a direction in Figure 2(c). Hydrogen bond interactions were listed in Supplementary Table SII.

TABLE II.

Crystal and experimental data Lumateperone tosylate

Figure 2.

(a) Asymmetric unit of Lumateperone tosylate shown in thermal ellipsoid model with 30% probability. (b) Molecular configuration diagram of Lumateperone. (c) 1D hydrogen bonding chains of Lumateperone tosylate viewed along the b axis.

Despite the use of careful grinding and sample rotation during measurement, an evidently preferred orientation was observed in the experimental XRD pattern due to the needlelike crystal morphology of Lumateperone tosylate. An orientation coefficient of 0.75 at the [002] direction (refined by WPF refinement in Jade) was added to the simulated pattern derived from the single-crystal data. The comparison of the experimental powder diffraction pattern and the simulated pattern is shown in Figure 3. Results showed that both single-crystal and powder diffraction methods can get similar structure data and the deviations of the unit-cell parameters and unit-cell volume were between 0.03% and 0.36%.

Figure 3.

X-ray powder diffraction pattern (black line) and the simulated pattern (red line) of the crystal structure with preferred orientation in the [002] direction (orientation coefficient = 0.75) (red line) of Lumateperone tosylate. The blue curve is the normalized error plot. The vertical scale has been multiplied by a factor 5× for 2θ >21°.

IV. DEPOSITED DATA

CIF and/or RAW data files were deposited with ICDD. You may request this data from ICDD at .

Supplementary material

The supplementary material for this article can be found at https://doi.org/10.1017/S0885715623000337.

Acknowledgements

This article was financially supported from the Experimental Technology Research Project of Zhejiang University (SYBJS202204) and the Natural Science Exploration Project of Zhejiang Province (LTGC23B050006).

References

REFERENCES

Blair, H. A. 2020. “Lumateperone: First Approval.” Drugs 80 (4): 417–23. doi:10.1007/s40265-020-01271-6CrossRefGoogle ScholarPubMed
Brandenburg, K., and Putz, H.. 2005. Diamond-Crystal and Molecular Structure Visualization. Bonn, Germany, Crystal Impact GbR.Google Scholar
Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., Li, J., Cheng, J., and Wang, S.. 2022. “Structure-Based Discovery of Nonhallucinogenic Psychedelic Analogs.” Science 375 (6579): 403–11. doi:10.1126/science.abl8615CrossRefGoogle ScholarPubMed
Dolomanov, O. V., Bourhis, L. J., Gildea, R. J., Howard, J. A. K., and Puschmann, H.. 2009. “OLEX2: A Complete Structure Solution, Refinement and Analysis Program.” Journal of Applied Crystallography 42 (2): 339–41. doi:10.1107/s0021889808042726CrossRefGoogle Scholar
Frampton, J. E. 2020. “Lumateperone in Schizophrenia: A Profile of its Use.” Drugs & Therapy Perspectives 36 (11): 477–84. doi:10.1007/s40267-020-00780-4CrossRefGoogle Scholar
Gates-Rector, S., and Blanton, T.. 2019. “The Powder Diffraction File: A Quality Materials Characterization Database.” Powder Diffraction 34 (4): 352–60. doi:10.1017/s0885715619000812CrossRefGoogle Scholar
Greenwood, J., Acharya, R. B., Marcellus, V., and Rey, J. A.. 2021. “Lumateperone: A Novel Antipsychotic for Schizophrenia.” Annals of Pharmacotherapy 55 (1): 98–104. doi:10.1177/1060028020936597CrossRefGoogle ScholarPubMed
Groom, C. R., Bruno, I. J., Lightfoot, M. P., and Ward, S. C.. 2016. “The Cambridge Structural Database.” Acta Crystallographica Section B: Structural Science 72: 171–79. doi:10.1107/S2052520616003954.CrossRefGoogle ScholarPubMed
Janton, N., Cerić, H., Matečić, M. S., Mrsic, N., Lerman, L., Momcilovic, T. D., Sagud, I., and Jegorov, A.. 2016. Solid State Forms of Lumateperone Ditosylate Salt. WO2018031535A1.Google Scholar
Janton, N., Cerić, H., Matečić, M. S., Mrsic, N., Lerman, L., Momcilovic, T. D., Sagud, I., and Jegorov, A.. 2018. Solid State Forms of Lumateperone Salts and Processes for Preparation of Lumateperone and Salts Thereof. WO2020112941A2.Google Scholar
Kumar, B., Kuhad, A., and Kuhad, A.. 2018. “Lumateperone: A New Treatment Approach for Neuropsychiatric Disorders.” Drugs Today 54 (12): 713–19. doi:10.1358/2018.54.12.2899443CrossRefGoogle ScholarPubMed
Lengauer, H., Pichler, A., and Margreiter, R.. 2019. Crystalline Salt of A 5-HT2A Receptor Antagonist. WO2020182978A1.Google Scholar
Li, P., and Wennogle, L. P.. 2017. Novel Salts and Crystals. WO2019067591A1.Google Scholar
Maini, K., Hollier, J. W., Gould, H., Bollich, V., John LaForge, J., Cornett, E. M., Edinoff, A. N., Kaye, A. M., and Kaye, A. D.. 2021. “Lumateperone Tosylate, A Selective and Concurrent Modulator of Serotonin, Dopamine, and Glutamate, in the Treatment of Schizophrenia.” Health Psychology Research 9 (1): 24932. doi:10.52965/001c.24932CrossRefGoogle ScholarPubMed
Materials Data Inc., (MDI). 2009. Jade 9.4 XRD pattern processing software.Google Scholar
Mazza, M., Marano, G., Traversi, G., Sani, G., and Janiri, L.. 2020. “Evidence on the New Drug Lumateperone (ITI-007) for Psychiatric and Neurological Disorders.” CNS & Neurological Disorders Drug Targets. 19 (4): 243–47. doi:10.2174/1871527319666200601145653CrossRefGoogle ScholarPubMed
Pahwa, M., Sleem, A., Elsayed, O. H., Good, M. E., and El-Mallakh, R. S.. 2021. “New Antipsychotic Medications in the Last Decade.” Current Psychiatry Reports 23 (12): 87. doi:10.1007/s11920-021-01298-wCrossRefGoogle ScholarPubMed
Sheldrick, G. M. 2015a. “SHELXT – Integrated Space-Group and Crystal-Structure Determination.” Acta Crystallographica. Section A, Foundations and Advances 71: 3–8. doi:10.1107/S2053273314026370CrossRefGoogle ScholarPubMed
Sheldrick, G. M. 2015b. “Crystal Structure Refinement with SHELXL.” Acta Crystallographica. Section C, Structural Chemistry 71: 3–8. doi:10.1107/S2053229614024218CrossRefGoogle ScholarPubMed
Smith, G. S., and Snyder, R. L.. 1979. “FN: A Criterion for Rating Powder Diffraction Patterns and Evaluating the Reliability of Powder-Pattern Indexing.” Journal of Applied Crystallography 12 (1): 60–65. doi:10.1107/s002188987901178xCrossRefGoogle Scholar
Syed, A. B., and Brasic, J. R.. 2021. “The Role of Lumateperone in the Treatment of Schizophrenia.” Therapeutic Advances in Psychopharmacology 11: 1–4. doi:10.1177/20451253211034019CrossRefGoogle ScholarPubMed
Titulaer, J., Radhe, O., Danielsson, K., Dutheil, S., Marcus, M. M., Jardemark, K., Svensson, T. H., Snyder, G. L., Ericson, M., Davis, R. E., and Konradsson-Geuken, A.. 2022. “Lumateperone-Mediated Effects on Prefrontal Glutamatergic Receptor-Mediated Neurotransmission: A Dopamine D(1) Receptor Dependent Mechanism.” European Neuropsychopharmacology 62: 22–35. doi:10.1016/j.euroneuro.2022.06.009CrossRefGoogle ScholarPubMed
Wennogle, L. P., and Tomesch, J.. 2008. Substituted Heterocycle Fused Gamma-carbolines Solid. WO2009114181A2.Google Scholar
Wennogle, L. P., Li, P., and Aret, E.. 2016. Novel Salts and Crystals. WO2017172784A1.Google Scholar
Figure 0

Figure 1. Chemical structure of Lumateperone.

Figure 1

TABLE I. X-ray powder diffraction data of Lumateperone tosylate

Figure 2

TABLE II. Crystal and experimental data Lumateperone tosylate

Figure 3

Figure 2. (a) Asymmetric unit of Lumateperone tosylate shown in thermal ellipsoid model with 30% probability. (b) Molecular configuration diagram of Lumateperone. (c) 1D hydrogen bonding chains of Lumateperone tosylate viewed along the b axis.

Figure 4

Figure 3. X-ray powder diffraction pattern (black line) and the simulated pattern (red line) of the crystal structure with preferred orientation in the [002] direction (orientation coefficient = 0.75) (red line) of Lumateperone tosylate. The blue curve is the normalized error plot. The vertical scale has been multiplied by a factor 5× for 2θ >21°.

Supplementary material: File

Liu et al. supplementary material

Liu et al. supplementary material

Download Liu et al. supplementary material(File)
File 312.2 KB